• Tumor response (complete or partial) on 2 consecutive evaluations at least 4-6 weeks apart [ Designated as safety issue: No ]
  

• Overall survival [ Designated as safety issue: No ]
  
• Time to progression [ Designated as safety issue: No ]
  

OBJECTIVES:

• Determine the response rate, time to progression, and survival in patients with advanced ovarian epithelial or primary peritoneal cancer treated with cisplatin and flavopiridol.
• Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are accrued to two separate groups (Group 2 closed to accrual as of 3/10/06).

• Group 1

  • Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

• Group 2

  • Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for up to 3 years.

PROJECTED ACCRUAL: A total of 38-79 patients (20-42 for group 1 and 18-37 for group 2 [Closed to accrual as of 3/10/06]) will be accrued for this study within 7-14 months.

DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial or primary peritoneal cancer

  • Advanced disease

• Meets at least 1 of the following criteria:

  • Measurable disease
  • Evaluable disease plus CA 125 ≥ 2 times post-treatment nadir

• Treated with 1, and only 1, prior chemotherapy regimen (e.g., paclitaxel or carboplatin-based) for ovarian epithelial or primary peritoneal cancer

  • Prior treatment with the same regimen at first relapse allowed

• Group 1, meeting 1 of the following criteria:

  • Patients who relapse during or < 6 months after completion of post-debulking chemotherapy
  • "Platinum sensitive" patients in second relapse after having been treated/rechallenged with their initial regimen upon first relapse

• Group 2 (Closed to accrual as of 3/10/06)

  • Patients who relapse ≥ 6 months after completion of post-debulking chemotherapy and are not retreated with the same or a different regimen
• No CNS metastases

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 10 g/dL* NOTE: *May be supported with transfusion, epoetin alfa, or darbepoetin alfa

Hepatic

• AST ≤ 2.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN
• Bilirubin ≤ 1.5 times ULN

Renal

• Creatinine ≤ 1.5 times ULN

Cardiovascular

• No cardiac arrhythmia
• No cardiac failure

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancy within the past 5 years except non-melanoma skin cancer or carcinoma in situ of the cervix
• No diabetes
• No peripheral neuropathy ≥ grade 2
• No baseline diarrhea (≥ 4 stools/day)
• No uncontrolled infection
• No other concurrent uncontrolled serious medical condition

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No concurrent routine colony-stimulating factors

Chemotherapy

• See Disease Characteristics
• More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)

Endocrine therapy

• Not specified

Radiotherapy

• More than 3 weeks since prior radiotherapy

Surgery

• Not specified

Other

• Recovered from all prior therapy